公开(公告)号：US20230330073A1

公开(公告)日：2023-10-19

申请号：US18306257

申请日：2023-04-25

Applicant: Prilenia Neurotherapeutics Ltd.

Inventor： Michael HAYDEN ,  Michal GEVA

IPC: A61K31/44 ,  A61P25/14 ,  A61K9/48

CPC classification number: A61K31/44 ,  A61P25/14 ,  A61K9/48

Abstract: This invention provides a method of maintaining, improving or lessening the decline of functional capacity or motor function in a human patient in a human patient with Huntington disease (HD) comprising orally administering to the patient a pharmaceutical composition comprising pridopidine.

公开(公告)号：US20230181548A1

公开(公告)日：2023-06-15

申请号：US18164587

申请日：2023-02-05

Applicant: Prilenia Neurotherapeutics Ltd.

Inventor： Michael HAYDEN ,  Michal GEVA

IPC: A61K31/44 ,  A61P25/14 ,  A61K9/48

CPC classification number: A61K31/44 ,  A61P25/14 ,  A61K9/48

Abstract: This invention provides a method of maintaining functional capacity, improving functional capacity, or lessening the decline of functional capacity in a human patient comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine such that a dose of 90 mg of pridopidine is administered to the patient per day, so as to thereby maintain functional capacity, improve functional capacity, or lessen the decline of functional capacity in the human patient.

公开(公告)号：US20210220342A1

公开(公告)日：2021-07-22

申请号：US17182605

申请日：2021-02-23

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michael HAYDEN ,  Michal GEVA ,  Ana Cristina CARVALHO REGO

IPC: A61K31/44 ,  A61P25/28

Abstract: The subject invention provides a method for treating a subject afflicted with a disease, disorder, or condition associated with mitochondrial dysfunction or ER stress, comprising administering to the subject a composition comprising pridopidine or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20200179355A1

公开(公告)日：2020-06-11

申请号：US16789564

申请日：2020-02-13

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal GEVA ,  Ralph LAUFER ,  Michael HAYDEN ,  Neta ZACH

IPC: A61K31/44 ,  A61K9/00 ,  A61K31/426 ,  A61K31/4152 ,  A61K31/49 ,  A61K31/222 ,  A61K31/185 ,  A61K31/4748 ,  A61P25/14

Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine as monotherapy or together with riluzole, edaravone, combination of dextromethorphan/quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid or combination of sodium phenylbutyrate (PB)/tauroursodeoxycholic acid (i.e. AMX0035) as combination or add-on therapy.